
usd jan pm et
summari compani provid advanc scientif instrument relat product servic
world-wide pharmaceut industri govern academ custom
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain
inc lift target
higher forward price-to-earnings
unchang ep estim line
histor forward price-to-earnings
averag reflect improv view
revenu despit on-going concern
qualiti earn growth keep
ep estim stand
mid-point pki ep guidanc
rang post ep
adjust revenu grew yoy
adjust ep continu grow even faster
yoy top-lin revenu growth driven
yoy growth main discoveri
analyt solut divis sale led
better-than-anticip growth life
scienc food franchis diagnost
segment sale grew yoy led
mid-teen growth immun produc
wide rang reagent medic laboratori
risk assess reflect strong track record
technolog innov divers global client
base firm strong posit rapidli
grow reproduct diagnost field provid
long-term demand tailwind see benefit
partial off-set somewhat volatil sale pattern
howev note sale growth neg
quarter also see risk
associ strength sever much larger
diversifi competitor particularli seek market
share gain area competitor may
alreadi firmli entrench
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice-president
corpor overview inc provid technolog product servic
diagnost research environment industri laboratori servic market compani oper
two segment discoveri analyt solut revenu oper profit
diagnost revenu oper profit
discoveri analyt solut da technolog product segment help life
scienc research better understand diseas develop treatment addit allow
monitor manag contamin toxic chemic impact environ food
suppli da serv life scienc appli market describ
life scienc market serv da consist research market laboratori servic market
life scienc product sold da support pharmaceut biotech compani academ
institut discov develop better treatment therapeut fight diseas da
onesourc laboratori servic busi also provid life scienc custom servic design improv
laboratori product time reduc mainten cost
appli market serv da consist environment food industri market environment
custom use da analyt technolog servic understand character
environ like air water soil qualiti exampl da solut help ensur complianc
regulatori standard protect puriti world water suppli detect harm substanc
includ trace metal lead organ pollut pesticid food produc use da
instrument confirm food qualiti includ level moistur grain level fat butter
well detect presenc potenti danger contamin lead mercuri milk
industri custom chemic semiconductor electron energi lubric petrochem
produc use da technolog primarili qualiti assur capac
diagnost segment sell product servic hospit medic lab clinician medic
research profession focu reproduct health autoimmun diseas screen appli
genom diagnost product use clinic set provid earli detect genet
disord pregnanc earli childhood also use infecti diseas test
segment also serv laboratori custom util instrument reagent softwar
test screen genet abnorm certain disord diseas includ syndrom
hypothyroid infertil variou metabol condit diagnost product also support
genom research analysi lab workflow use next-gener dna sequenc applic
oncolog drug discoveri
employ approxim sale servic repres countri directli market
servic product across globe market lack sale servic forc util
third-parti distributor get product custom
product sold often serv custom conduct cutting-edg research develop
 biopharmaceut medic industri applic accordingli must consist invest
 provid product anticip continu evolv need technolog
advanc custom base spent million revenu program
corpor strategi histor pursu capit alloc strategi balanc small
bolt-on acquisit share repurchas dividend debt reduct deviat
strategi howev make major acquisit expand diagnost busi acquir immun
decemb billion increas invest capit compar
immun lead diagnost compani focus autoimmun infecti diseas allergi test
manag decemb prahlad singh appoint ceo replac robert franci
friel step end chairman ceo consid singh focu next
phase growth evolut believ could right path forward compani
financi trend sale grown billion billion repres
three-year compound annual growth rate compound-annual-growth-rate sale growth materi impact
immun acquisit drove sale increas adjust pre-tax incom per
share grew three-year compound-annual-growth-rate period aid expans adjust
pre-tax incom margin signific financi
leverag risk view ebita-to-interest coverag roughli
sustain dividend polici view histor compani balanc sheet
low moder debt level net debt/ebitda rang rang last ten year net
debt/ebitda stood septemb view allow distribut cash
dividend everi quarter amount per share period decemb
offer dividend yield dividend pay-out ratio stood
expect continu pay dividend maintain similar low dividend yield
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc octob technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year expect earn growth
remain posit slow sharpli
rate achiev posit
earn growth view
healthi fund public medic research
demand growth emerg market expect
factor balanc slower
biopharmaceut spend growth
neg effect trade tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect mark
major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
expect publicly-fund client think
biopharmaceut firm moder
 spend growth year ahead
estim total
spend
biopharmaceut compani grew
annual averag expect slow
howev
mani biopharmaceut firm look limit
spend growth off-set recent
revenu headwind patent expir
public scrutini high drug price larg
swath biopharma typic flow
lst firm suppli depart
research tool softwar contract servic
accordingli think slowdown
biopharma growth reduc tailwind
mani lst firm receiv
client group recent year
final recent escal trade tariff
neg impact lst earn
growth view expect
continu analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
first half brought lower profit
mani busi think shift
relat escal tariff impos
 -china trade
soften demand -made
instrument china rais product
cost instrument maker limit
suppli chain flexibl end sight
current trade disput expect tariff
continu pressur sale growth
oper margin sub-industri
year-to-d septemb
 life scienc tool
servic rose broader
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra maintain buy opinion share thermo fisher scientif
inc maintain price target ep estim
share major analyt instrument maker sharpli
today includ
around midday believ sell-off partial relat
ad chines firm export blacklist monday increas tension
trade war view hurt global suppli chain
instrument maker disagre reaction share howev
think compani global divers product facil uniqu lack
single-sourc suppli relationship give much greater flexibl peer
avoid tariff-driven cost increas view advantag actual allow
take signific instrument market share smaller firm like
etc reli china revenu wherea
gener roughli sale /colin scarola
pm et cfra maintain sell opinion share inc
drop target price ep estim --
roughli line histor forward price-to-earnings averag maintain
ep estim ep vs met consensu revenu
grew yoy led diagnost segment oper profit
continu perform well top line revenu growth yoy
discoveri analyt grew sale yoy howev demand
analyt instrument china significantli weaken quarter think
 -china trade war neg impact cost competit
busi segment saw adjust oper margin worsen yoy
addit cash oper first half fell
yoy receiv inventori grow mid-teen versu
low-singl digit revenu think balanc sheet trend put
risk miss futur revenu growth oper margin target /colin
analyst research note compani news
et cfra maintain hold opinion share inc
lift target higher forward price-to-earnings
unchang ep estim line
histor forward price-to-earnings averag reflect improv view follow
better-than-expect adj ep revenu despit on-going concern
qualiti earn growth keep ep estim
stand mid-point pki ep guidanc rang
post ep vs consensu beat
pki adjust revenu grew yoy adjust ep continu
grow even faster yoy top-lin revenu growth driven yoy
growth main discoveri analyt solut divis sale
led better-than-anticip growth life scienc food franchis
diagnost segment sale grew yoy led mid-teen growth
immun produc wide rang reagent medic laboratori
pm et cfra maintain hold opinion share inc
lift target higher revis price-to-earnings
ep estim slightli pki histor forward price-to-earnings
averag maintain ep estim rais
rais reflect improv
outlook follow resolut phase one deal
china chines sale make roughli pki total revenu
tariff-driven cost increas pose signific econom risk compani
view moreov believ appoint prahlad singh ceo
could right path forward compani consid
singh focu next phase growth evolut yet
remain cautiou qualiti earn growth prefer remain neutral
spike receiv inventori day could indic
may extend custom payment term combat weaken demand
age inventori view sel hardi
et cfra maintain hold opinion share inc
keep target price ep estim --
histor forward price-to-earnings averag lift ep estim
lower start adjust ep
vs beat consensu grew revenu yoy
adjust ep even faster yoy howev see sever reason
question qualiti earn growth one doubl
non-gaap adjust purchas account restructur despit
signific recur expens busi strategi
without larg yoy increas adjust ep growth closer
yoy well consensu addit concern respect day
yoy increas receiv day inventori day indic us
may extend custom payment term combat weaken demand
inventori concern inform hold opinion despit peer
et cfra lift opinion share inc hold
sell drop target price ep
estim maintain ep estim sell
recommend share sinc april concern
forward price-to-earnings valuat roughli becom rich compar
averag respect neg impact
analyt instrument margin escal border tariff
fulli appreci view share declin sinc sell
recommend compar flat perform
forward price-to-earnings multipl compress bring share much closer
fair valu estim accordingli move share hold still expect
tariff drive market share loss discoveri analyt segment
think strong posit rapidli grow reproduct
diagnost market warrant slight valuat premium
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
